No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Becton, Dickinson and Company (BD) operates as a global medical technology enterprise, specializing in the development, manufacturing, and distribution of a diverse portfolio of medical supplies, advanced devices, laboratory equipment, and diagnostic solutions. Their offerings serve a broad spectrum of clients worldwide, including healthcare institutions, medical practitioners, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The BD Medical division provides essential products for patient care and medication management. This encompasses various catheters, such as peripheral IV, central venous, and acute dialysis catheters, alongside vascular access and preparation items, needle-free IV connectors, and closed-system drug transfer devices. It also addresses hazardous drug detection. The segment supplies a wide array of injection and safety products, including hypodermic syringes, needles, anesthesia kits, enteral syringes, and sharps disposal systems. Additionally, BD Medical delivers integrated solutions for IV medication delivery and infusion therapy, sophisticated compounding workflow systems, automated medication dispensing and supply management tools, and inventory optimization systems. For diabetes care, it offers syringes and pen needles, as well as prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostic and research advancements. It offers products for specimen and blood collection, in addition to automated systems for blood and tuberculosis culturing, molecular diagnostics, microorganism identification, and drug susceptibility testing. This division also provides liquid-based cytology systems, rapid diagnostic assays, advanced microbiology laboratory automation, and plated media. For cellular analysis and clinical diagnostics, the segment features fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression analysis, along with diagnostic and monitoring reagents and analyzers for clinical oncology, immunology, and transplantation. Lastly, the BD Interventional segment focuses on specialized products for surgical and interventional procedures. Its product range includes devices for hernia and soft tissue repair, biological and bioresorbable grafts, and general biosurgery items. It further provides solutions for surgical infection prevention, alongside surgical and laparoscopic instrumentation. This segment also covers peripheral intervention devices, and dedicated products for urology and critical care. Founded in 1897, the company's corporate headquarters are located in Franklin Lakes, New Jersey.
www.bd.comNo one on the platform currently holds 0R19.L.
No tracked institution reports a position in 0R19.L as of their last filing.
No one on the platform has traded 0R19.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.1% | 5.6% | 6.4% | — | — | — |
| Rev. Growth % | 8.2% | 6.3% | ||||
| Profit Margin % | 7.7% | 8.8% | 7.6% | |||
| Free Cash Flow Margin % | 12.2% | 13.0% | 13.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $19.3B | -11.7% | $12.67 | $12.62–$12.73 | — | 1 |
| 2027 | $19.7B | +2.1% | $13.29 | $13.24–$13.35 | — | 1 |
| 2028 | $20.4B | +3.8% | $14.17 | $14.11–$14.24 | — | 1 |
| 2029 | $21.1B | +3.4% | $15.23 | $15.16–$15.30 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $3.14 | $3.23 | +2.9% |
| 2026-05-07 | $2.78 | $2.90 | +4.3% |
| 2026-02-09 | $2.21 | $2.29 | +3.6% |
| 2025-11-06 | $3.08 | $3.11 | +1.0% |
| 2025-08-07 | $2.67 | $2.89 | +8.2% |
| 2025-05-01 | $2.58 | $2.63 | +1.9% |
| 2025-02-06 | $2.34 | $2.70 | +15.4% |
| 2024-11-07 | $2.96 |
| $2.99 |
| +1.0% |
| -1.13% |
| $54.8B |
| — |
| 0J6Z.LHumana Inc. | $392.79 | -0.71% | $47.2B | — |
| 0J8P.LIDEXX Laboratories, Inc. | $519.55 | +1.61% | $41.0B | — |
Source: Financial Modeling Prep · peers by sector/industry